Event

Paolo Spagnolo

MD PhD
UNIVERSITA STUDI DI PADOVA;Università degli Studi di Padova, Clinica di Malattie dell'Apparato Respiratorio;Universita Studi Di PAdova

Wibke Stansen

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Christopher J. Ryerson

M.D.
Centre for Heart Lung Innovation, University of British Columbia;Univeristy of British Columbia and St. Paul's Hospital;University of British Columbia

Francesco Bonella

MD
Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hopsital, University of Duisburg

Marlies Wijsenbeek

MD, PhD
Erasmus MC, University Medical Centre;Erasmus Medical Center;Erasmus University Medical Center

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Predicted Versus Observed Mortality in Clinical Trials of Nintedanib in Idiopathic Pulmonary Fibrosis (IPF)